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Abstract: The effect of solvent removal techniques on phase transition, physical stability and
dissolution of bicalutamide from solid dispersions containing polyvinylpyrrolidone (PVP) as a
carrier was investigated. A spray dryer and a rotavapor were applied to obtain binary systems
containing either 50% or 66% of the drug. Applied techniques led to the formation of amorphous
solid dispersions as confirmed by X-ray powder diffractometry and differential scanning calorimetry.
Moreover, solid–solid transition from polymorphic form I to form II was observed for bicalutamide
spray dried without a carrier. The presence of intermolecular interactions between the drug
and polymer molecules, which provides the stabilization of molecularly disordered bicalutamide,
was analyzed using infrared spectroscopy. Spectral changes within the region characteristic for
amide vibrations suggested that the amide form of crystalline bicalutamide was replaced by a less
stable imidic one, characteristic of an amorphous drug. Applied processes also resulted in changes
of particle geometry and size as confirmed by scanning electron microscopy and laser diffraction
measurements, however they did not affect the dissolution significantly as confirmed by intrinsic
dissolution study. The enhancement of apparent solubility and dissolution were assigned mostly to
the loss of molecular arrangement by drug molecules. Performed statistical analysis indicated that the
presence of PVP reduces the mean dissolution time and improve the dissolution efficiency. Although
the dissolution was equally affected by both applied methods of solid dispersion manufacturing,
spray drying provides better control of particle size and morphology as well as a lower tendency for
recrystallization of amorphous solid dispersions.
Keywords: bicalutamide; PVP; solid dispersion; spray drying; evaporation; dissolution; amorphization
1. Introduction
The amorphization of active pharmaceutical ingredients (APIs) and the characterization of the
properties of molecularly disordered solid-state have attracted attention in recent years. Its formation
occurs when a molten crystalline substance is rapidly cooled down as the molecules have not had
enough time to move from their current position to a thermodynamically stable position on the crystal
lattice and to rearrange into an ordered system [1]. The formed supercooled liquid state remains in
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equilibrium with the molten substance until reaching the glass transition temperature (Tg), at which a
glassy state exhibiting only short range order is achieved. This second order thermodynamic transition
is associated with an increase in enthalpy, entropy, volume and free energy of the amorphous state in
comparison to its crystalline counterpart [2,3].
Although the crystalline state offers the advantages of good chemical and physical stability as
well as high purity, the lattice energy barrier often affects drug solubility. The absence of the long-range
order leads to higher molecular mobility of the system which enables it to reach supersaturation and
consequently a higher overall dissolution rate. It is of particular importance in the drug development
as approximately 46% of APIs fall into class II of the biopharmaceutical classification system due to
poor solubility in water and dissolution rate-limited oral absorption [4].
The increase in apparent solubility of amorphous drugs is an advantage, however the inherent
stability remains as a major limitation. The systems tend to recrystallize upon introduction to the
aqueous environment, either through precipitation from the supersaturated solution during the
dissolution process or upon storage through contact with moisture in the air. The nucleation and the
crystallization of amorphous material is accelerated above the Tg due to the increased mobility of the
disordered system; thus, it is postulated to assess the molecular dynamics of the molecular system and
to manufacture compounds with a high glass transition temperature. It is particularly challenging for
drugs with low Tg (e.g., paracetamol) as the excess free energy leads to spontaneous transformation
to the crystalline state. Thus, drug-polymer systems have been introduced as they show improved
stability in comparison to amorphous drugs alone [5].
Due to their complex three-dimensional (3D) architecture, macromolecules hinder the molecular
mobility of amorphous systems, lowering their chemical potential and preventing devitrification.
The formation of solid dispersions with polymers having high Tg values leads to the antiplasticization
of the API molecules which is manifested by the increase in Tg combined with the increase of free
energy required for crystallization. The glass transition of the mixture can be calculated by use of the
Gordon–Taylor equation [6]. Other factors which drive the formation of amorphous solid dispersions
exhibiting enhanced dissolution are the interactions between drug and polymer molecules as well as
the type and parameters of the applied process.
The term solid dispersion describes the systems in which one or more APIs are molecularly
dispersed within an inert carrier. The two main manufacturing techniques rely on melting and
evaporating the solvent [7]. In the fusion method, the heating of a mixture of the drug and polymer
is followed by fast cooling that leads to solidification of the molten system. Although this method is
very simple and frequently used, it faces several limitations resulting from the limited miscibility of
APIs and the carriers, as well as the thermal lability of drug molecules [8]. The solvent-based methods
solve these problems as the drug and the carrier are dissolved in a volatile solvent such as ethanol,
ethyl acetate, methanol or an ethanol–methylene chloride mixture which can be removed without
heating [9,10]. Laboratory solvent evaporation techniques can be divided into several groups such as
rotary evaporation, spray drying and freeze drying. In a rotary evaporator, the solvent is removed
under vacuum at an only slightly elevated temperature which prevents the decomposition of the
drug or the carrier. Although the complete removal of the solvent is almost impossible and residual
solvent may cause toxicity and plasticize the system leading to phase separation, the method has been
successfully applied to the preparation of solid dispersions containing celocoxib [11], nifedipine [12],
itraconazole [13] and stiripentol [14].
The spray drying process is a very efficient technique for manufacturing solid dispersions as it
provides rapid solvent removal and fast formation of solid API-carrier particles [15]. Moreover, it
is a scalable technique that provides the possibility of continuous manufacturing, good uniformity
of molecular dispersion and a low production cost on an industrial scale [7]. It has been described
in the manufacturing of solid dispersions containing celocoxib [16], tadalafil [17], itraconazole [18]
and glibenclamide [19]. Moreover, spray drying was used for the preparation of marketed products
such as Incivek® and Intelence® [20]. This technique comprises of four processes: the atomization of
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the liquid with the dissolved or suspended drug, which is transported into the nozzle and sprayed
onto fine droplets; the mixing of the liquid with the drying gas; and the evaporation and separation of
obtained particles from the gas by the use of cyclone [21]. The size of the droplets can be modulated
via the nozzle and thus spray drying is used as a technique for particle engineering, leading to particle
size reduction. Moreover, this technique provides amorphization of APIs which results in significant
improvement in their solubility and dissolution rate.
The results reported herein describe the amorphization of bicalutamide (BCL)—a non-steroidal
antiandrogenic drug used in prostate cancer treatment. This poorly-soluble compound is assigned to BCL
class II due to its low solubility in water (<3.7 mg/L) and high membrane permeability (logP = 2.92) [22].
Moreover, it has two polymorphic forms and easily undergoes mechanical activation [23–26]. In our
research, we applied a rotary evaporator and spray dryer in order to obtain solid dispersions containing
an equal amount of bicalutamide and polyvinylpyrrolidone (PVP) as well as the system with an excess
of the carrier. The effect of the applied process on phase transition, physical stability, saturation
solubility and the dissolution kinetics of BCL was investigated. X-ray diffraction measurements,
differential scanning calorimetry and infrared spectroscopy were applied to study process-induced
phase transitions of the drug. The physical stability of the amorphous solid dispersions were analyzed
as well. The morphology and particle size distribution were assessed by scanning electron microscopy
and laser diffraction.
2. Materials and Methods
2.1. Materials
Bicalutamide (BCL, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy
-2-methylpropanamide, 99.8%, Hangzhou Hyper Chemicals Limited, Zhejiang, China) was used as
the model drug. Polyvinylpyrrolidone K29/32 (PVP, Ashland, Covington, KY, USA) was used as
an excipient. Sodium lauryl sulfate (SLS, BASF, Ludwigshafen am Rhein, Germany) was used to
prepare the dissolution medium. Ethanol (absolute, 99.8%, pure p.a., Avantor Performance Materials,
Gliwice, Poland) was used as a solvent in evaporation processes. Cyclohexane (ACS, pure p.a., Avantor
Performance Materials, Gliwice, Poland) was used as a dispersant in laser diffraction measurements.
All chemicals were used as received. Distilled water was used to prepare all of the aqueous solutions.
2.2. Solvent Evaporation
Bicalutamide (1.5 g) was dissolved in 200 mL of ethanol and mixed with PVP at a 1:1 and 2:1
weight (wt.) ratio, respectively. The solution was heated up to 40 ◦C in a water bath and after complete
dissolution of the mixture, the solvent was evaporated under reduced pressure using a Hei-VAP Value
rotavapor (Heidolph, Schwabach, Germany). The rotational speed was 200 rpm and the pressure was
reduced stepwise to approximately 50 mbar. Obtained samples were stored under vacuum for 24 h
prior further characterization.
2.3. Spray Drying
Ethanolic solutions containing bicalutamide and PVP were obtained similarly to those for solvent
evaporation and spray dried using a Mini Spray Dryer B-191 (Büchi, Flawil, Switzerland). The process
was conducted using the following parameters: inlet temperature = 50 ◦C, outlet temperature = 42 ◦C,
aspirator flow = 100%, gas flow rate = 600 L/min, liquid flow rate = 3.4 mL/min, diameter of
nozzle = 0.7 mm. The process was carried out under constant control and the concentration of ethanol
was 10 times lower than the flammability limit. The samples were further dried under vacuum to
remove residual solvent. The yields were approximately 60–70%.
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2.4. Scanning Electron Microscopy (SEM)
The morphological features of samples were determined using a Phenom Pro desktop electron
microscope (PhenomWorld, Thermo Fisher Scientific, Waltham, MA, USA) equipped with a CeB6
electron source and a backscattered electron detector. The powder was placed on the conductive
adhesive tape previously glued to the specimen mount. The sample excess (loosely bound to the
tape) was removed using a stream of argon. The acceleration voltage was equal to 10 kV and the
magnification was 500× and 1000× for evaporated samples, and 5000× for spray dried systems.
The measurements were performed without further processing.
2.5. Differential Scanning Calorimetry (DSC)
The thermodynamic properties of the samples were examined using a DSC 1 STARe System
(Mettler–Toledo, Greifensee, Switzerland) equipped with a HSS8 ceramic sensor with 120 thermocouples
and a liquid nitrogen cooling station. The measuring device was calibrated for temperature and enthalpy
using zinc and indium standards. Crystallization and melting points were determined as the onset
of the peak, whereas the glass transition temperature was determined as the midpoint of the heat
capacity increment. The samples were measured in an aluminum crucible (40 µL). All measurements
were carried out with the heating rate equal to 10 K/min.
2.6. Powder X-ray Diffraction (PXRD)
The diffraction patterns of the samples were registered at ambient temperature within the angular
range of 3–70◦ using a Mini Flex II X-ray diffractometer (Rigaku, Tokyo, Japan) with 5◦/min step of
size equal to 0.02. Monochromatic Cu Kα radiation (λ = 1.5418 Å) was used.
2.7. Laser Diffraction Measurements
Particle size distribution was determined using a Mastersizer 3000 (Malvern Instruments, Malvern,
UK) equipped with a HydroEV unit. Samples were analyzed by the wet method using cyclohexane
(refractive index, RI = 1.426) as a dispersant. Fraunhofer diffraction theory was applied to find the
relationship between particle size and the light intensity distribution pattern. Reported data represents
the averages from ten series of measurements of each sample.
2.8. Infrared Spectroscopy (FTIR)
A Nicolet iS10 FT-IR spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped
with the Smart iTR™ ATR sampling accessory with diamond as the ATR crystal was used. Spectra
of powders were collected within the range 600–4000 cm−1 with 4 cm−1 resolution, 128 scans for
each sample.
2.9. Dissolution Study
The dissolution of BCL was determined using the method recommended by the FDA for
BCL tablets (1000 mL of 1% SLS, 50 rpm, 37 ± 0.5 ◦C) in the pharmacopeial paddle dissolution
apparatus Vision Elite 8 (Hanson Research, Chatsworth, CA, USA) equipped with VisionG2 AutoPlus
Autosampler. Pure drug and binary systems, equivalent to 50 mg of BCL, were placed into the
beakers. The sink conditions were maintained. The samples were filtered and analyzed at 272 nm at
predetermined periods of time using a UV-1800 spectrophotometer (Shimatzu, Kioto, Japan) equipped
with flow-through cuvettes. The tests were carried out in triplicate and presented results represent
averages with their standard deviations (mean ± SD).
2.10. Intrinsic Dissolution Rate Study
The compacts for intrinsic dissolution studies were prepared using a Specac 50 hydraulic press
(Specac, Kent, UK) by compressing powder systems directly into the stainless steel cylinders with a
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0.5026 cm2 flat surface area and 2 tons of pressure applied for 30 s. The cylinders were then mounted
in the Hanson Vision G2 Elite 8 dissolution apparatus (Hanson Research, Chatsworth, California,
USA) and stirred with a rotation speed of 100 rpm. The dissolution vessels were filled with 500 mL
of 1% SLS solution maintained at 37 ◦C. The amount of dissolved BCL was assayed online using a
UV-1800 spectrophotometer (Shimadzu, Kioto, Japan) at λ = 272 nm. The intrinsic dissolution rate was
calculated based on the accessible surface area as a function of mass ratio of the components in the
mixture. Ten points were used for the construction of intrinsic dissolution profiles of each system and
four of them were used to calculate the intrinsic dissolution rate (IDR) values.
2.11. Solubility Study
An excess of processed bicalutamide or BCL–PVP binary systems of both type (i.e., evaporated
and spray dried) was dispersed in 25 mL of distilled water. The suspensions were shaken at room
temperature for 24 h using the KS 130 basic orbital shaker (IKA, Staufen im Breisgau, Germany).
The samples were centrifuged at 3600 rpm for 20 min in the MPW 221 apparatus (MPW MED
Instruments, Warsaw, Poland) and filtered through a 0.45 µm Chromafil®Xtra CA-45/25 membrane
filter. The samples were assayed in triplicate at λ = 270 nm using a UV-1800spectrophotometer
(Shimadzu, Kioto, Japan). The reported data represents the averages from three series of measurements
with standard deviations (mean ± SD).
2.12. Statistical Analysis
The KinetDS v3.0 software was used to determine the dissolution kinetics of BCL. Three mathematical
models (zero order, Korsmeyer–Peppas, and Hixson–Crowell) were fitted to the individual dissolution
data. To assess the goodness of fit, the coefficient of determination was calculated in combination
with the analysis of variance (alpha < 0.01). Moreover, the models’ independent parameters, such as
dissolution efficiency (DE) and mean dissolution time (MDT) were also calculated.
3. Results and Discussion
3.1. Molecular Arrangement
3.1.1. X-ray Powder Diffraction Studies
The molecular structure of solid dispersions and bicalutamide processed using either a rotavapor
or a spray dryer indicates that the drug undergoes structural changes (Figure 1). The sharp Braggs
peaks in the diffractogram registered for raw BCL confirm that bicalutamide exists as a form
I polymorph [27]. The long-range order was not affected in the evaporation process as the diffraction
pattern is almost unchanged with only a slight decrease in the relative intensity of peaks in the range
of 15–25◦. This indicates the recrystallization of BCL during the solidification and the reconstruction of
the monoclinic crystal lattice characteristic for form I polymorphs. Interestingly, there were different
Braggs peaks of bicalutamide after spray drying and the diffraction pattern was less structured than
the one obtained for the evaporated sample. The peaks can be assigned to polymorphic form II, which
indicates that spray drying of bicalutamide led to phase transition. Moreover, obtained results indicate
that storing samples for six months did not lead to structural changes of either evaporated or spray
dried samples (dotted lined in Figure 1). What is worth mentioning is that form II is metastable and it
usually undergoes solid–solid transition into the more stable form I [28]. Results presented in Figure 1
indicate that spray dried bicalutamide exists as a form II polymorph even after six months when stored
at ambient temperature. No shifts or peak displacement were noticed in the diffraction pattern.
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Figure 1. X-ray diffraction patterns of crystalline bicalutamide (BCL) and BCL–PVP (polyvinylpyrrolidone)
binary systems obtained by either evaporation (E) or spray drying (SD) measured two days (solid lines)
and six months (dotted lines) after preparation.
The samples containing PVP were found to be totally amorphous as no structured diffraction
patterns were noticed. The broad halo confirms that the molecular structure of binary systems
is disordered and that PVP sufficiently prevents the recrystallization of bicalutamide from both
evaporated and spray dried systems. The samples containing a two-fold excess of the drug in
comparison to the ass of the carrier did not differ from those containing an equal mass of BCL and
PVP. This is particularly important for further applications as it may reduce the amount of auxiliary
substance in t e final dosage form. It also confirms that PVP serves as a good stabilizer for upercooled
BCL and the excess of the carrier is not obligatory. It stays in contradiction with previously published
papers where the concentration of PVP providing stabilization for the amorphous form of bicalutamide
exceeded 80% [29,30]. In performed studies, both types of systems (i.e., containing either 50% or
33% of the carrier) were totally amorphous. After six months, broad halos were registered for all
binary systems and no signs of recrystallization were noticed. This is of particular importance as
molecularly-disordered BCL usually recrystallizes into a form II polymorph within days and further
into the most stable form I. The addition of PVP prevented the reconstruction of the crystal lattice.
Importantly, research focused on the physical stability of the glassy state of bicalutamide confirmed that
PVP hindered recrystallization of the drug. Szczurek et al. applied broadband dielectric spectroscopy
and estimated the physical stability of amorphous bicalutamide would be approximately 145 years
for a BCL–PVP 2:1 binary system when stored at room temperature [31]. Humidity effect was not
considered, which makes that estimation more theoretical.
3.1.2. DSC Studies
Thermal properties of BCL and BCL–PVP solid dispersions obtained by either spray dryer or
rotavapor have been investigated using the DSC technique. The samples were heated from 273 K to
483 K at a rate of 10 K/min. The DSC thermograms of neat BCL prepared by employing two different
methods are compared to crystalline samples (as purchased) and presented in Figure 2a. As can be
seen, none of the applied methods led to BCL amorphization. On the DSC thermograms, one can
observe the endothermic peak in the vicinity of 470 K, corresponding to the drug melting. It is worth
highlighting that even if the amorphization had failed, some differences between evaporated and
spray dried BCL exist. In the DSC thermogram of the spray dried sample, one can observe that the
position of the endothermic peak is slightly shifted to a lower temperature in comparison to the initial
BCL, which may indicate the formation of a type II polymorph. In the case of the evaporated BCL,
the melting peak is at the same position as in the case of the initial sample.
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solid dispersions (b).
Since either spray drying or evaporation methods were not able to convert the neat BCL to its
amorphous form, samples containing PVP were prepared accordingly. The DSC thermograms of all
obtained solid dispersions are presented in Figure 2b. For each sample, two separate experiments
were performed. During the first experiment, the sample was heated from 273 K to 483 K at a
rate of 10 K/min as in the case of neat BCL. The second experiment consisted of three segments:
(i) 15-min annealing of the sample at 353 K, (ii) cooling the sample to 273 K at a rate of 10 K/min
and (iii) heating the sample in the same way as in the case of the first experiment. As can be seen,
all DSC thermograms obtained without annealing of BCL–PVP solid dispersions are characterized by
the broad endothermic peak in the vicinity of 340–380 K. Since this peak vanished after annealing, one
might conclude that it reflects the water evaporation. The DSC thermograms of BCL–PVP 1:1 obtained
after the annealing procedure are characterized by a single step-like glass transition thermal event.
On the thermogram of the BCL–PVP 2:1 systems, next to a glass transition event, an exothermic peak
representing cold crystallization followed by endothermic peak reflecting the melting of BCL can be
observed. The temperatures taken as the midpoint of the samples glass transition and the onsets of
cold crystallization and melting are shown in Table 1. The presence of either Tg or Tc indicates that all
samples containing drug and polymer were amorphous. Obtained results shows that the larger the
amount of PVP, the higher the values of Tg. The shift in the glass transition temperature, as well as the
lack of cold crystallization in BCL–PVP 1:1, indicates that such a system should be more physically
stable than BCL–PVP 2:1 when stored at standard storage conditions. Due to the fact that the BCL–PVP
2:1 system prepared by evaporation re-crystallizes at a lower temperature, it is characterized by lower
physical stability than its spray dried counterpart. Consequently, it can be concluded that spray drying
is the better method for the production of BCL-based amorphous solid dispersions.
Table 1. Comparison of the glass transition temperature (Tg), Tc and Tm values of binary systems
containing BCL and PVP.
Process Sample Tg (K) Tc (K) Tm (K)
Spray drying BCL–PVP 1:1 (SD) 375 - -
BCL–PVP 2:1 (SD) 357 416 444; 446
Evaporation BCL–PVP 1:1 (E) 376 - -
BCL–PVP 2:1 (E) 357 396 449
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3.1.3. Infrared Spectroscopy
FTIR studies were used to analyze the interactions between bicalutamide co-processed with
PVP, as they may be important factors for the stabilization of amorphous solid dispersion (Figure 3).
Moreover, spectroscopic characteristics of the binary systems, i.e., peak intensity, shape, width and
position, can be used to distinguish polymorphs and amorphous forms of the compound. The spectrum
of raw BCL abounds in peaks characteristic to polymorphic form I [27] with well-structured peaks
of the stretching vibrations of functional groups, i.e., C=O at 1687 cm−1, N-H at 3336 cm−1, O-H
between 3558–3609 cm−1 and C≡O at 1326 cm−1 [23]. Solvent removal in a rotavapor did not cause
significant changes in the spectrum of bicalutamide processed without a carrier. A shift of the CO
absorption band towards higher wavenumbers was observed only for spray dried drug, which
indicates the formation of a form II polymorph [27]. The differences were well pronounced for systems
containing bicalutamide and PVP. They were most visible in two spectral regions: 1600–1800 cm−1 and
3200–3600 cm−1. The shift and the broadening of the band corresponding to C=O stretching vibration
in binary systems indicates that the components of solid dispersion interact intermolecularly, which
can be responsible for the stabilization of molecularly disordered systems as confirmed by XRPD and
DSC measurements. Moreover, the band at 3336 cm−1 almost disappeared, which suggests that the
amide form of crystalline bicalutamide was replaced by a less stable imidic one characteristic of an
amorphous drug [32].
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3.2. Particle Size and Morphology
3.2.1. Morphology of Particles from Scanning Electron Microscopy
SEM analysis indicates that spray drying led to significant morphological changes of processed
samples as seen in Figure 4. The formation of spherical particles was observed. Their diameter did not
exceed 10 µm for BCL spray dried alone (Figure 4A) and with PVP (1:1 wt. ratio, Figure 4C) and 15 µm
for BCL spray dried with PVP at a 2:1 wt. ratio (Figure 4B). While particles of the drug co-processed
with PVP are smooth, the surface of BCL spray dried particles seems to be more rough (they look like
cotton-balls, see insert in Figure 4A).
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During the evaporation process, bicalutamide undergoes recrystallization and a reduction in
particle size was observed. Formed crystals adopt a plate-like shape and tend to aggregate into
agglomerates not exceeding 120 µm in length (Figure 5A), whilst for raw BCL, elongated hexagons of
approximately 150 µm in length were observed [23]. Particles obtained after solvent removal from
systems containing BCL and PVP also adopt plate-like shapes, however they are bigger (exceed 200 µm)
(Figure 5B,C).
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Figure 5. SEM images of evaporated systems: BCL (A), BCL–PVP 2:1 (B) and BCL–PVP 1:1 (C).
3.2.2. Particle Size Distribution from Laser Diffraction Measurements
Data obtained from SEM analysis corresponds well with particle size determination utilizing laser
diffraction (Table 2). Spray drying led to the formation of particles not exceeding 70 µm in diameter,
while the particles of evaporated samples are greater than 200 µm for solid dispersions and 50 µm for
bicalutamide processed without a carrier.
Table 2. Particle size distribution results obtained using the laser diffraction method.
Process Sample Dv 10 (µm) Dv 50 (µm) Dv 90 (µm)
Spray drying
BCL–PVP 1:1 (SD) 3.6 16.4 34.9
BCL–PVP 2:1 (SD) 4.6 17.1 60.1
BCL (SD) 5.3 15.0 38.5
Evaporation
BCL–PVP 1:1 (E) 80.0 352.0 1087.0
BCL–PVP 2:1 (E) 54.1 252.0 672.0
BCL (E) 14.5 55.1 251.0
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The obtained particle size distribution of evaporated samples is monomodal (BCL–PVP systems),
broad and slightly tailed towards low particle size (Figure 6). It correlates with previously described
SEM data where particles of various sizes were observed. Interestingly, the distribution of particles of
BCL after solvent removal by means of evaporation exhibits two maxima, one at approximately 30 µm
and one at 200 µm. This may be due to an aggregation of small plate-like particles into a bigger one.
Moreover, the distribution is shifted towards lower size values in comparison to those collected for
co-processed samples. The size distributions of spray dried systems confirm the formation of much
smaller particles than after evaporation (Figure 6). It is clearly visible that there are particles of a
diameter below 1 µm (in each system), which may affect the equilibrium solubility. The maxima of the
distributions of particles obtained by spray drying are located within a similar range, below 20 µm.
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3.3. Dissolution Study
Papers published so far reported formation of amorphous bicalutamide by means of the formation
of solid dispersion with PVP utilizing solvent evaporation; however, an excessive amount of a carrier
was required [29,30]. The drug was only totally morphous whe the content of the polymer exceeded
80%. This was concluded as a disadvantage in further formulation studies as it may lead to an increase
in the bulkiness and weight of the tablets.
To face that limitation, we prepared BCL–PVP binary systems co taining either an equal amount
of both substances or twice as much BCL as the carrier. The dis olution profiles prese ted in Figure 7
showed approximately 10-fold improvement in bicalutamide dissolution from solid dispersions in
comparison to the untreated drug where only 8.2% of the API dissolved. This may be explained by
drug amorphization as molecularly disordered systems exhibit improved dissolution. Interestingly,
while the amount of drug dissolved from evaporated sa ples does not differ significantly between the
two investigated systems (less than 3%, i.e., 83.85± 4.04% for 1:1 solid dispersion and 86.59± 1.21% for
the 2:1 binary system), variations between spray dried systems are more pronounced (approximately
10%, i.e., 78.51 ± 3.36% for the 1:1 system and 89.29 ± 2.27% for 2:1 solid dispersion). However,
both of the applied methods lead to imilar dissolution profiles and the total amo nt of dissolved
drug indicates that the dissolution behavior is affected strongly by the molecular characteristic of the
sample (the excess of free energy possessed by the amorphous state). The effect of different size and
morphology of solid-state p rticles is less significant. The phase transition from polymorphic form I to
form II resulted in a eight-f ld improvement of spray ried bicalutamid dis olution as 72.33 ± 5.91%
of drug dissolved. As there were no differences in particle morphology and size between bicalutamide
spray dried alone and with PVP, we assumed that the effect of particle size reduction is of minor
importance. Importantly, evaporation did not result in structural changes of the drug molecule and
the four-fold improvement in bicalutamide dissolution (34.14 ± 1.05% after 1 h) was concluded to be
the result of particle size reduction and slightly decreased crystallinity of the sample in comparison
to raw BCL. Regardless of the method of preparation of solid dispersion, more of the drug dissolved
from the BCL–PVP 2:1 binary system. It confirms that the excess of PVP is not required for either BCL
dissolution enhancement or for stabilization of the amorphous form of the drug.
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3.4. Saturation Solubility
The solubility of bicalutamide spray dried alone is twice as much as the unprocessed drug.
This may be a result of phase transition from polymorph I to polymorph II, which exhibits over
two-fold higher solubility. Observed improvement can also be a consequence of particle size reduction
(Figure 8). While the solubility theory suggests that the effect of particle size reduction on equilibrium
solubility is slightly noticeable, the Ostwald–Freundlich equation indicates that the relative increase in
compound activity (and thus solubility) related to particle size reduction becomes significant below
1 µm. This assumption was adopted from the phenomena described by Kelvin for gas–liquid systems
where the increased vapor pressure and liquid transfer into the gas phase was related to increased
curvature (decreased radii) of the liquid droplets [33]. In solid–liquid systems, the reduction of particle
size affects neither the efficiency of solvation nor the properties of the solid state, however below 1 µm,
the solvation pressure increases, causing an increase in solubility [34]. According to SEM images and
particle size distribution from laser diffraction measurements, there is a fraction of particles with a
diameter below 1 µm; this could be responsible for the observed increase in solubility of bicalutamide
spray dried without a carrier. No improvement in evaporated bicalutamide was noticed.
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For systems co-processed with PVP, the increase in solubility varied between 2.6-fold for the 2:1
evaporated system to 6.7-fold for the 2:1 spray dried mixture. No significant variations between spray
dried samples were observed and similarly to dissolution tests, a better result was obtained for the 2:1
system. Interestingly, evaporated samples varied in saturation solubility as the value determined for
1:1 solid dispersion was two times greater than for the 2:1 binary system. This conforms with the DSC
data, as evaporated samples, especially those containing an excess of the drug, tend to recrystallize
faster than spray dried ones.
3.5. Intrinsic Dissolution Study
The intrinsic dissolution measurements have been recently studied and discussed as an important
tool in pharmaceutical research and development. It allows the characterization of the crystalline
forms and polymorphs of pure drugs and drug formulations by exposing a constant surface area to
the dissolution medium. It has been also introduced for the solubility determination as an alternative
method to equilibrium solubility [35,36].
Performed intrinsic dissolution studies showed significant differences in the dissolution behavior
that is not affected by either particle size distribution or porosity (Figure 9). In case of evaporated binary
systems, compacts underwent erosion and the presence of freely floating particles in the dissolution
medium might cause slightly enhanced dissolution and consequently overestimated values of IDR.
The observed behavior of compacts may be a result of the plate-like shape of the particles and indicates
poor tabletability of this system.
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Yellow square indicates the range used to calculate the intrinsic dissolution rate (IRD) values.
The intrinsic dissolution rate (IDR) values presented in Table 3 clearly confirm that faster
dissolution was obtained for the systems prepared by spray drying. It can be also noticed that a
1:1 concentration of BCL and PVP promotes faster dissolution in both preparation methods as the
IDR for these samples was higher in comparison to 2:1 binary systems. This may result from the
faster dissolution of the hydrophilic carrier and increase of the BCL surface available for the solvent.
It can also be concluded that the processing of bicalutamide itself in a rotary evaporator did not
affect the intrinsic dissolution rate significantly, while spray drying slightly increases the intrinsic
dissolution rate.
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Table 3. Values of intrinsic dissolution rates of crystalline bicalutamide, drug processed alone and
binary systems containing bicalutamide and PVP obtained using the evaporation technique (E) and
spray drying (SD).
Process Sample IDR (mg/cm2/min)
- Raw BCL 0.0144
Spray drying
BCL-PVP 1:1 (SD) 0.0796
BCL-PVP 2:1 (SD) 0.0411
BCL (SD) 0.0204
Evaporation
BCL-PVP 1:1 (E) 0.0992
BCL-PVP 2:1 (E) 0.0523
BCL (E) 0.0131
3.6. Statistical Analysis
The drug dissolution mechanism was explained by fitting the zero order, Korsmeyer–Peppas,
and Hixson–Crowell mathematical models (Table 4) using the KinetDS v3.0 software [37,38].
The highest coefficients of determination (r2) were found for Korsmeyer–Peppas models. Considering
the coefficients of determination (r2) and the significance of ANOVA tests, three formulations
failed to fit the chosen models (BCL-PVP 1:1 (SD), BCL-PVP 2:1 (SD) and BCL-PVP 1:1 (E)). Fitted
Korsmeyer–Peppas models for pure BCL (processed or not) indicate that the dissolution from these
formulations is diffusion-driven and may be connected to the crystalline or recrystallized form (Table 5).
Moreover, the BCL-PVP 2:1 (E) formulation seems to follow diffusion-based kinetics after the first stage
of fast dissolution. Although the fitting of the models failed for spray dried formulations consisting of
BCL and PVP, the highest values of the coefficient of determination for the Korsmeyer–Peppas model
may suggest that bicalutamide can be dissolved by diffusion (r2 = 0.7916–0.8413) rather than by the
erosion-based mechanism (r2 = 0.5014–0.5611) or the zero order kinetics (r2 = 0.5043–0.5796).
Table 4. Employed mathematical models.
Function Equation
First-order Q = k · t+Q0
Korsmeyer–Peppas Q = k · tn
Hixson–Crowell Q
1
3 = k · t+Q0 13
n is the release exponent; Q, percent of drug dissolved at time t; Q0, percent of drug dissolved at time t = 0; k,
dissolution rate constant.
In general, according to the calculated model independent parameters, it is observed that the
addition of PVP reduces the mean dissolution time (MDT) by two- to three-fold. The shortest MDT
was obtained for a formulation prepared by the spray drying technique (BCL-PVP 2:1). The longest
MDT was observed for BCL alone prepared by the evaporation technique. Therefore, PVP increases
the dissolution efficiency by three-fold in case of evaporation processing and by 1.5-fold for the spray
dried samples in comparison to drug processed alone.
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Table 5. Parameters, determination coefficients and statistical significance of dissolution kinetics models.
Formulation
MDT
(min)
DE
(%)
Mathematical Model
Zero Order Korsmeyer–Peppas Hixson–Crowell
(Constant Release) (Diffusion Based Release) (Erosion Based Release)
Raw BCL
(not processed) 19.55 5.58
k = 0.1037
Q0 = 2.4571
r2 = 0.9594
p = 0.0035
k = 1.0895
n = 0.5002
r2 = 0.9981
p < 0.0001
k = 0.0117
Q0 = 2.66
r2 = 0.9036
p = 0.0114
BCL (E) 20.65 22.39
k = 0.4455
Q0 = 8.9816
r2 = 0.9686
p = 0.0024 *
k = 3.8641
n = 0.5362
r2 = 0.9991
p < 0.0001 *
k = 0.0199
Q0 = 10.02
r2 = 0.9131
p = 0.0096 *
BCL (SD) 15.99 53.05
k = 0.8489
Q0 = 27.25
r2 = 0.9040
p = 0.0130
k = 12.2261
n = 0.4501
r2 = 0.9827
p = 0.0011 *
k = 0.0216
Q0 = 28.13
r2 = 0.8440
p = 0.0263
BCL-PVP 1:1 (SD) 6.28 70.30
k = 0.4905
Q0 = 55.90
r2 = 0.5796
p = 0.1350
k = 35.4591
n = 0.2164
r2 = 0.8413
p = 0.0358
k = 0.0104
Q0 = 55.06
r2 = 0.5611
p = 0.1540
BCL-PVP 2:1 (SD) 3.60 83.93
k = 0.1530
Q0 = 82.11
r2 = 0.5043
p = 0.1790
k = 73.9170
n = 0.0512
r2 = 0.7916
p = 0.0464
k = 0.0027
Q0 = 82.02
r2 = 0.5014
p = 0.1840
BCL-PVP 1:1 (E) 7.65 73.17
k = 0.5099
Q0 = 58.37
r2 = 0.4847
p = 0.1920
k = 35.4333
n = 0.2287
r2 = 0.7469
p = 0.0769
k = 0.0107
Q0 = 56.933
r2 = 0.4759
p = 0.2100
BCL-PVP 2:1 (E) 5.19 79.11
k = 0.2097
Q0 = 75.53
r2 = 0.8494
p = 0.0260
k = 67.22
n = 0.0632
r2 = 0.9917
p = 0.0003 *
k = 0.0037
Q0 = 75.55
r2 = 0.8394
p = 0.0284
r2, determination coefficient; MDT, mean dissolution time; DE, dissolution efficiency; k, dissolution rate constant;
Q0, percent of drug dissolved at time t = 0; n is the release exponent; p is the probability of ANOVA test for similarity
(* <0.01).
4. Conclusions
In this paper, we analyzed the effect of solvent evaporation techniques on physical stability and
dissolution of bicalutamide from solid dispersions containing PVP as a carrier. Obtained results
indicate that both applied methods, namely spray drying and evaporation utilizing a rotary evaporator,
led to amorphization of bicalutamide as confirmed by X-ray diffractometry and DSC measurements.
The presence of intermolecular interactions between the drug and polymer confirmed by FTIR
spectroscopy was found to provide stabilization of the molecularly-disordered system. Importantly,
the concentration of PVP that provided sufficient stabilization of amorphous bicalutamide was 33% wt.
while the previously published papers reported as much as a five-fold excess of the carrier.
The loss of molecular arrangement by drug molecules led to its enhanced dissolution. Over a
10-fold improvement was noticed in comparison to the untreated drug. Moreover, the solubility of
solid dispersions in water was also improved from 3.7 mg/L to as much as 24.9 mg/L. Interestingly,
the solubility of bicalutamide spray dried without PVP led to a two-fold enhancement which resulted
from phase transition into a form II polymorph. Statistical analysis confirmed that addition of PVP led
to the increase of dissolution efficiency and significant decrease of mean dissolution time in comparison
to raw bicalutamide and the drug processed alone.
The removal of solvent led to morphological changes in the particles. Bicalutamide polymorphic
form I that crystallizes in a monoclinic lattice system appears as elongated hexagons, while spray
drying (with or without PVP) led to the formation of spherical particles with a diameter below 15 µm.
Applying the rotary evaporator resulted in the formation of plate-like particles of irregular shape
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exceeding 100 µm and exhibiting a wide size distribution. While the dissolution was equally affected
by both applied methods of solid dispersion manufacturing, spray drying provided better control of
particle size and morphology as well as a lower tendency for recrystallization of amorphous solid
dispersions. Thus, it is more useful in the pharmaceutical industry.
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